[Calcium antagonists in chronic renal failure. Undesirable effects on glomerular hemodynamics?]. 1988

O Mickisch, and M Schmid, and J F Mann, and T Helder, and F Bergen, and E W Rauterberg, and E Ritz
Medizinische Klinik Institut für Immunologie und Serologie, Universität Heidelberg.

Seven patients with glomerular proteinuria and hypertension (six with biopsy confirmation of glomerulonephritis, one with proteinuria after unilateral nephrectomy) were randomly given, for 14 days each, a calcium antagonist and then a conversion enzyme inhibitor, or vice versa, following a 14-day pause of all medication. Fractional albuminuria rose significantly during administration of calcium antagonists (P less than 0.05), while it decreased significantly during administration of converting enzyme inhibitor (P less than 0.05). The explanation for this finding may be that calcium antagonists raise glomerular capillary pressure by dilating the afferent arterioles, while converting enzyme inhibitors predominantly cause dilatation of the efferent arterioles.

UI MeSH Term Description Entries
D006977 Hypertension, Renal Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN. Hypertensions, Renal,Renal Hypertension,Renal Hypertensions
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007678 Kidney Glomerulus A cluster of convoluted capillaries beginning at each nephric tubule in the kidney and held together by connective tissue. Glomerulus, Kidney
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D004656 Enalapril An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE. Enalapril Maleate,MK-421,MK421,Renitec,Renitek,MK 421,Maleate, Enalapril
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

O Mickisch, and M Schmid, and J F Mann, and T Helder, and F Bergen, and E W Rauterberg, and E Ritz
May 1992, Kidney international. Supplement,
O Mickisch, and M Schmid, and J F Mann, and T Helder, and F Bergen, and E W Rauterberg, and E Ritz
June 1996, Kidney international. Supplement,
O Mickisch, and M Schmid, and J F Mann, and T Helder, and F Bergen, and E W Rauterberg, and E Ritz
October 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation,
O Mickisch, and M Schmid, and J F Mann, and T Helder, and F Bergen, and E W Rauterberg, and E Ritz
November 1985, The American journal of physiology,
O Mickisch, and M Schmid, and J F Mann, and T Helder, and F Bergen, and E W Rauterberg, and E Ritz
June 1994, Archives of internal medicine,
O Mickisch, and M Schmid, and J F Mann, and T Helder, and F Bergen, and E W Rauterberg, and E Ritz
May 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation,
O Mickisch, and M Schmid, and J F Mann, and T Helder, and F Bergen, and E W Rauterberg, and E Ritz
August 1991, Journal of the American Society of Nephrology : JASN,
O Mickisch, and M Schmid, and J F Mann, and T Helder, and F Bergen, and E W Rauterberg, and E Ritz
March 1997, Renal failure,
O Mickisch, and M Schmid, and J F Mann, and T Helder, and F Bergen, and E W Rauterberg, and E Ritz
January 1991, Nephron,
O Mickisch, and M Schmid, and J F Mann, and T Helder, and F Bergen, and E W Rauterberg, and E Ritz
August 1987, Kidney international,
Copied contents to your clipboard!